NCT06620796View on ClinicalTrials.gov

A Phase II Study of Ivonescimab Combined with Cadonilimab and Chemotherapy in Extensive-stage Small Cell Lung Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2027

Conditions
SCLC, Extensive Stage
Interventions
DRUG

Arm 1

Ivonescimab combined with Cadonilimab plus EC

DRUG

second-line group

AK112+AK104+paclitaxel

All Listed Sponsors
lead

Shanghai Pulmonary Hospital, Shanghai, China

OTHER

NCT06620796 - A Phase II Study of Ivonescimab Combined with Cadonilimab and Chemotherapy in Extensive-stage Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter